
Claims

1. Use of a compound of the formula Ia:



(Ia)

wherein:

R^1 is NH_2;

R^2 is H;

R^{13} is phenyl, optionally substituted with 1, 2 or 3 R^{22};

R^{15} is methyl;

R^{16} is 2-pentyl;

each R^{22} is independently selected from halo, C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, phenyl, hydroxyC_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkylcarbonyl, C_3-C_6cycloalkylcarbonyl, carboxyC_1-C_6alkyl, hydroxy, amino CN, and NO_2, or any two R^{22} groups attached to adjacent ring carbon atoms can combine to form -O-$(CR^{23}R^{23'})_{1\text{-}6}$-O-;


R^{23} and $R^{23'}$ are independently H or C_1-C_3alkyl;

or a pharmaceutically acceptable salt and/or solvate thereof, in the preparation of a medicament for the treatment of liver cancer, wherein a therapeutically effective amount of the compound is to be administered orally to a warm blooded animal.

2. The use according to claim 1, wherein R^{13} is substituted with one or two R^{22}.

3. The use according to claim 1, wherein R^{13} is unsubstituted phenyl.


4. The use according to claim 1, wherein the compound of formula Ia is:



.


or a pharmaceutically acceptable salt thereof.

5. The use according to claim 1, wherein the compound of formula Ia is



or a pharmaceutically acceptable salt thereof.

6. The use according to claim 1, wherein the compound of formula Ia is



or a pharmaceutically acceptable salt thereof.

7. The use according to any one of clams 1 to 6, wherein the liver cancer is hepatocellular carcinoma.

8. The use according to any one of claims 1 to 6, wherein the liver cancer is a secondary liver cancer, that is a cancer that has originated in an organ elsewhere in the body and has metastasised to the liver.

9. The use according to claim 8, wherein the cancer has metastasised to the liver from colon, lung or breast.

10. The use according to any one of claims 1 to 9, wherein the warm-blooded animal is a human.